Recently, there has been much progress in the design and application of oil-repellent superoleophobic surfaces. Polyzwitterionic brush surfaces are of particular interest, because of their ability to repel oil under water, even in the absence of micro-/nano-structures. The origin of this underwater superoleophobicity is attributed to the presence of a stable water film beneath the oil droplet, but this had not been demonstrated experimentally. Here, using optical interferometric techniques, we show that an oil droplet effectively hydroplanes over a water film, whose thickness is between one hundred and hundreds of nanometres. In addition, using a custom-built Droplet Force Apparatus, we measured the friction and adhesion forces to be in the nN range for millimetric-sized droplets. These forces are much lower than for other classes of well-known liquid-repellent surfaces, including the lotus-leaf effect and lubricant-infused surfaces, where the typical force is on the order of µN. arXiv:1906.09910v2 [cond-mat.soft]

Psoriatic arthritis (PsA) is a chronic inflammatory disease that presents with psoriasis (PsO), peripheral and axial arthropathy. The heterogeneity of disease presentation leads to the term “psoriatic disease (PsD)” which is thought to better encompass the range of clinical manifestations. PsA is associated with several comorbidities such as cardiovascular diseases, metabolic syndrome and other extra-articular manifestations including uveitis, and inflammatory bowel disease (IBD). While novel therapeutics are being developed following advances in our understanding of the pathogenesis of the disease, the diverse combinations of PsA with its various comorbidities still pose a clinical challenge in managing patients with PsA. This article reviews our current understanding of the pathogenesis of PsA and how various pathways in the pathogenesis lead to the two comorbid extra-articular manifestations – uveitis and IBD. We also review current evidence of treatment strategies in managing patients with PsA with comorbidities of uveitis and/or IBD.

No abstract